118 related articles for article (PubMed ID: 9890197)
21. Tenascin-C as predictor of left ventricular remodeling and mortality in patients with dilated cardiomyopathy.
Sarli B; Topsakal R; Kaya EG; Akpek M; Lam YY; Kaya MG
J Investig Med; 2013 Apr; 61(4):728-32. PubMed ID: 23429699
[TBL] [Abstract][Full Text] [Related]
22. Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy.
Adamopoulos S; Parissis JT; Paraskevaidis I; Karatzas D; Livanis E; Georgiadis M; Karavolias G; Mitropoulos D; Degiannis D; Kremastinos DT
Eur Heart J; 2003 Dec; 24(24):2186-96. PubMed ID: 14659770
[TBL] [Abstract][Full Text] [Related]
23. Serum levels of soluble Fas in patients with Graves' ophthalmopathy.
Ohtsuka K; Hashimoto M
Br J Ophthalmol; 2000 Jan; 84(1):103-6. PubMed ID: 10611108
[TBL] [Abstract][Full Text] [Related]
24. Serum sFas and tumor tissue FasL negatively correlated with survival in Egyptian patients suffering from breast ductal carcinoma.
El-Sarha AI; Magour GM; Zaki SM; El-Sammak MY
Pathol Oncol Res; 2009 Jun; 15(2):241-50. PubMed ID: 19015953
[TBL] [Abstract][Full Text] [Related]
25. Soluble Fas is a marker of peripheral arterial occlusive disease in haemodialysis patients.
Masse M; Hébert MJ; Troyanov S; Vigneault N; Sirois I; Madore F
Nephrol Dial Transplant; 2002 Mar; 17(3):485-91. PubMed ID: 11865097
[TBL] [Abstract][Full Text] [Related]
26. [Role of soluble Fas ligand in myocardial remodeling, severity and outcomes of chronic heart failure].
Teplyakov AT; Berezikova EN; Shilov SN; Grakova EV; Torim YY; Efremov AV; Popova AA; Pustovetova MG; Sabirova AY; Kopyeva KV
Ter Arkh; 2016; 88(9):10-16. PubMed ID: 27735908
[TBL] [Abstract][Full Text] [Related]
27. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases.
Nozawa K; Kayagaki N; Tokano Y; Yagita H; Okumura K; Hasimoto H
Arthritis Rheum; 1997 Jun; 40(6):1126-9. PubMed ID: 9182923
[TBL] [Abstract][Full Text] [Related]
28. Significance of dyslipidaemia in patients with heart failure of unexplained aetiology.
Skwarek M; Bilińska ZT; Mazurkiewicz Ł; Grzybowski J; Kruk M; Kurjata P; Piotrowski W; Ruzyłło W
Kardiol Pol; 2008 May; 66(5):515-22, discussion 523-4. PubMed ID: 18537059
[TBL] [Abstract][Full Text] [Related]
29. Left ventricular reverse remodeling with infantile dilated cardiomyopathy and pitfalls of carvedilol therapy.
Tsuda E; Negishi J; Noritake K; Iwasa T; Abe T
J Cardiol; 2016 Feb; 67(2):147-52. PubMed ID: 26572957
[TBL] [Abstract][Full Text] [Related]
30. Soluble Fas: a novel predictor of atherosclerosis in dialysis patients.
Troyanov S; Hébert MJ; Masse M; Vigneault N; Sirois I; Madore F
Am J Kidney Dis; 2003 May; 41(5):1043-51. PubMed ID: 12722039
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
[TBL] [Abstract][Full Text] [Related]
32. Circulating miR-185 might be a novel biomarker for clinical outcome in patients with dilated cardiomyopathy.
Yu M; Liang W; Xie Y; Long Q; Cheng X; Liao YH; Yuan J
Sci Rep; 2016 Sep; 6():33580. PubMed ID: 27645404
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of troponin I efflux and troponin autoantibodies in patients with dilated cardiomyopathy.
Miettinen KH; Eriksson S; Magga J; Tuomainen P; Kuusisto J; Vanninen EJ; Turpeinen A; Punnonen KR; Pettersson K; Peuhkurinen KJ
J Card Fail; 2008 Aug; 14(6):481-8. PubMed ID: 18672196
[TBL] [Abstract][Full Text] [Related]
34. Proinflammatory cytokines, soluble Fas receptor, nitric oxide and angiotensin converting enzyme in congestive heart failure.
El Sherif WT; El Tooney LF; Meki AR; Abdel Moneim A
Egypt J Immunol; 2005; 12(1):39-48. PubMed ID: 16734138
[TBL] [Abstract][Full Text] [Related]
35. Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy.
Sliwa K; Woodiwiss A; Candy G; Badenhorst D; Libhaber C; Norton G; Skudicky D; Sareli P
Am J Cardiol; 2002 Nov; 90(10):1118-22. PubMed ID: 12423714
[TBL] [Abstract][Full Text] [Related]
36. Serum levels of soluble fas in patients with multinodular goiter.
Andrikoula M; Kolaitis N; Vartholomatos G; Tsatsoulis A
Immunol Invest; 2009; 38(5):398-407. PubMed ID: 19811416
[TBL] [Abstract][Full Text] [Related]
37. Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease.
Goel N; Ulrich DT; St Clair EW; Fleming JA; Lynch DH; Seldin MF
Arthritis Rheum; 1995 Dec; 38(12):1738-43. PubMed ID: 8849345
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Impact of Hypertrabeculation and Noncompaction Phenotype in Dilated Cardiomyopathy: A CMR Study.
Amzulescu MS; Rousseau MF; Ahn SA; Boileau L; de Meester de Ravenstein C; Vancraeynest D; Pasquet A; Vanoverschelde JL; Pouleur AC; Gerber BL
JACC Cardiovasc Imaging; 2015 Aug; 8(8):934-46. PubMed ID: 26189121
[TBL] [Abstract][Full Text] [Related]
39. Increased circulating interleukin 10-secreting B cells in patients with dilated cardiomyopathy.
Guo Y; Cen Z; Wei B; Wu W; Zhou Q
Int J Clin Exp Pathol; 2015; 8(7):8107-14. PubMed ID: 26339378
[TBL] [Abstract][Full Text] [Related]
40. Serum levels of soluble Fas/APO-1 receptor in human retroviral infection and associated diseases.
Kamihira S; Yamada Y; Hiragata Y; Yamaguchi T; Izumikawa K; Matsuo Y; Sugahara K; Tsuruta K; Atogami S; Tsukasaki K; Maeda T; Tomonaga M
Intern Med; 1997 Mar; 36(3):166-70. PubMed ID: 9144006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
